noscript

News and Announcements

Actinogens’ Xanamem™ to Showcase Cortisol Hypothesis

  • Published June 30, 2016 10:08AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

29th Sydney 2016, ASX Announcement

Actinogen Medical (ASX:ACW) is pleased to announce the key data supporting its novel Alzheimer’s drug Xanamem™, has been selected by an independent expert panel for presentation at the world’s largest dementia research conference – the Alzheimer’s Association International conference (AAIC), in Toronto 22nd – 28th July, 2016.

The presentation entitled, “Xanamem™ a novel 188-HSD1 inhibitor with as potential to provide durable symptomatic and disease modifying benefits in Alzheimer’s disease“, will include results on Xanamem™’s succesful Phase I human trials and importantly confirm that following oral administration Xanamem™’s effectively crosses the blood-brain-barrier and gets to the brain, its primary site of action in Alzheimer’s disease.

To view the full announcement, please click on the button below.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now